EMAIL THIS PAGE TO A FRIEND

Breast cancer research : BCR

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.


PMID 25212826

Abstract

Activation of the phosphatidylinositol 3-kinase (PI3K) pathway in estrogen receptor α (ER)-positive breast cancer is associated with reduced ER expression and activity, luminal B subtype, and poor outcome. Phosphatase and tensin homolog (PTEN), a negative regulator of this pathway, is typically lost in ER-negative breast cancer. We set out to clarify the role of reduced PTEN levels in endocrine resistance, and to explore the combination of newly developed PI3K downstream kinase inhibitors to overcome this resistance. Altered cellular signaling, gene expression, and endocrine sensitivity were determined in inducible PTEN-knockdown ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer cell and/or xenograft models. Single or two-agent combinations of kinase inhibitors were examined to improve endocrine therapy. Moderate PTEN reduction was sufficient to enhance PI3K signaling, generate a gene signature associated with the luminal B subtype of breast cancer, and cause endocrine resistance in vitro and in vivo. The mammalian target of rapamycin (mTOR), protein kinase B (AKT), or mitogen-activated protein kinase kinase (MEK) inhibitors, alone or in combination, improved endocrine therapy, but the efficacy varied by PTEN levels, type of endocrine therapy, and the specific inhibitor(s). A single-agent AKT inhibitor combined with fulvestrant conferred superior efficacy in overcoming resistance, inducing apoptosis and tumor regression. Moderate reduction in PTEN, without complete loss, can activate the PI3K pathway to cause endocrine resistance in ER-positive breast cancer, which can be overcome by combining endocrine therapy with inhibitors of the PI3K pathway. Our data suggests that the ER degrader fulvestrant, to block both ligand-dependent and -independent ER signaling, combined with an AKT inhibitor is an effective strategy to test in patients.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

40311
2-Butanone, 5000 μg/mL in methanol: water (9:1), analytical standard
C4H8O
02469
2-Butanone, analytical standard
C4H8O
W217018
2-Butanone, ≥99.5%, FCC, FG
C4H8O
48877
2-Butanone solution, certified reference material, 2000 μg/mL in methanol: water (9:1)
C4H8O
1250008
Estradiol, United States Pharmacopeia (USP) Reference Standard
C18H24O2
PHR1353
Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material
C18H24O2
I4409
Fulvestrant, >98% (HPLC)
C32H47F5O3S
Y0001399
Fulvestrant, European Pharmacopoeia (EP) Reference Standard
C32H47F5O3S
PHR1207
Methyl Ethyl Ketone, Pharmaceutical Secondary Standard; Certified Reference Material
C4H8O
M9140
Methylene blue, certified by the Biological Stain Commission
C16H18ClN3S · xH2O
03978
Methylene Blue solution, for microscopy, concentrate according to Ehrlich, concentrated, aqueous solution
C16H18ClN3S
1808
Methylene Blue solution, 1.4 % (w/v) in 95% ethanol
C16H18ClN3S
319112
Methylene Blue solution, 0.05 wt. % in H2O
C16H18ClN3S
77515
Methylene Blue solution, for microscopy
C16H18ClN3S
50484
Methylene Blue solution, for microbiology
C16H18ClN3S
66725
Methylene Blue solution alkaline according to Loeffler, according to Loeffler
C16H18ClN3S
T0014000
Tamoxifen citrate, European Pharmacopoeia (EP) Reference Standard
C26H29NO · C6H8O7
T0015000
Tamoxifen citrate for performance test, European Pharmacopoeia (EP) Reference Standard
C26H29NO · C6H8O7
T9262
Tamoxifen citrate salt, ≥99%
C26H29NO · C6H8O7
688053
Tris(4-carbazoyl-9-ylphenyl)amine, 97%
C54H36N4